Form 4: STRATA director trims stake, then buys back

Director Samuel Rubinstein sold 14,094 STRATA Skin Sciences shares and bought 5,000 the next day, ending with 8,766 shares at ~$1.32–$1.41 on Nov. 17–18, 2025.

Summary

• Director Samuel Rubinstein executed multiple open-market trades in STRATA Skin Sciences (SSKN) on Nov. 17–18, 2025.
• Sales on 11/17/2025: 5,500 shares at $1.32; 7,200 shares at $1.34; 1,394 shares at $1.36.
• Purchases on 11/18/2025: 2,168 shares at $1.40; 2,832 shares at $1.41.
• Ending beneficial ownership: 8,766 shares (direct).
• Implied starting beneficial ownership before 11/17 trades: 17,860 shares; net change: −9,094 shares.
• Estimated gross sale proceeds: $18,803.84; purchase cost: $7,028.32; net cash from activity: $11,775.52 (calculated from reported prices and quantities).

Sentiment

Score: 4

Explanation: Net reduction of ~51% in holdings indicates modestly negative insider sentiment, partially offset by next-day purchases and continued ownership.

Positives

• Insider purchased 5,000 shares on 11/18/2025 at $1.40–$1.41 following the prior day’s sales.
• Maintains a direct ownership position of 8,766 shares after the transactions.

Negatives

• Net reduction of 9,094 shares versus pre-transaction holdings (from 17,860 to 8,766; approximately −50.9%).
• Three separate sale tranches on 11/17/2025 at $1.32–$1.36 indicate meaningful trimming by a director.

Future Outlook

No forward-looking guidance; disclosure pertains solely to insider share transactions.

Industry Context

Insider transactions in small-cap medtech can influence sentiment but do not provide operating performance data. The mixed activity (sales followed by purchases) offers limited signal on fundamentals given small dollar amounts.

Comparison to Industry Standards

• No operating metrics (revenue, EBITDA, margins) were disclosed; comparison to peer financial benchmarks is not applicable.
• Insider transaction value (~$18.8k sales; ~$7.0k purchases) is small relative to typical market-moving insider trades in U.S. small-cap medtech, suggesting limited standalone impact.

Stakeholder Impact

• Shareholders may view the net insider sale as a modest negative signal, though the subsequent purchases and continued holdings soften the signal.
• No effect on employees, customers, suppliers, or creditors indicated.

Key Dates

Keywords

STRATA Skin Sciences, SSKN, insider trading, Form 4, Samuel Rubinstein, director transactions, beneficial ownership, open market sale, open market purchase, medical device, dermatology